Anti-ICAM-3 monoclonal antibody ICM3

Drug Profile

Anti-ICAM-3 monoclonal antibody ICM3

Alternative Names: ICM 3

Latest Information Update: 05 Jul 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ICOS Corporation
  • Class Monoclonal antibodies
  • Mechanism of Action Intercellular adhesion molecule 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Crohn's disease; Graft-versus-host disease; Psoriasis; Transplant rejection

Most Recent Events

  • 05 Jul 2001 Discontinued-Preclinical for Acute myeloid leukaemia in USA (Unknown route)
  • 05 Jul 2001 Discontinued-Preclinical for Crohn's disease in USA (Unknown route)
  • 05 Jul 2001 Discontinued-Preclinical for Graft-versus-host disease in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top